Human ARL6IP6 HEK293 Overexpression Lysate from MyBioSource.com

Supplier Page

Supplier Page from
MyBioSource.com for
Human ARL6IP6 HEK293 Overexpression Lysate

Get Pricing

Description

It had been found that a homozygous truncating mutation in ARL6IP6 as the likely cause of a syndromic form of CMTC associated with major dysmorphism, developmental delay, transient ischemic attacks and cerebral vascular malformations. This gene was previously implicated by genome wide association study (GWAS) as a susceptibility locus to ischemic stroke in young adults. We identify ARL6IP6 as a novel candidate gene for a syndromic form of CMTC. This suggests that ischemic stroke or transient ischemic attacks (TIA) may represent, at least in some cases, the mild end of a phenotypic spectrum that has at its severe end autosomal recessive CMTC. This finding contributes to a growing appreciation of the continuum of Mendelian and common complex diseases.

This Human ARL6IP6 overexpression lysate was created in HEK293 Cells and intented for use as a Western blot (WB) positive control. Purification of ARL6IP6 protein from the overexpression lysate was verified